Open in interactive viewer → charts, metric popovers & call review

Medical Facilities Grew 10% Without Growing — and Nobody Showed Up to Ask

Revenue rose 9.8% on a 1.6% decline in surgical cases, the Sioux Falls headwind that dominated six straight calls has finally vanished, and the Q&A line was empty again
DR.TO · Earnings Call · 2026-11-12

Growth Without Growth

The headline out of Medical Facilities Corporation's Q3 reads clean. Revenue of $65.9 million, up 9.8% year over year. Income from operations to $11.2 million, up 17.3%. EBITDA to $14.1 million, up 13.5%. For a company with a market cap under CAD 200 million, that is a violent amount of operating leverage. But then read the volume line: “Total surgical case volume was down 1.6%, with inpatient, observation, and outpatient cases declining 3.4%, 2%, and 1.3% respectively.” — David Watson, Chief Financial Officer · 2026-11-12 Even stripping out the low-margin dental business, volumes were down 0.6%. So the entire 9.8% top line came from price and mix, not from more bodies on gurneys. That is not a scandal — it is the whole business model, and management says so plainly: “Our case mix, combined with a favorable payer mix, drove a 9.8% increase in facility service revenue and improved profitability in the quarter.” — Jason Redman · 2026-11-12 Higher-acuity orthopedics, more spine procedures, more pain management cases, and negotiated payer rate increases did the work. The catch: Case mix is the oldest sentence in this company's vocabulary. It was the single largest keyword gainer in the entire recorded history of these calls — momentum 194 back in 20212 — and it has resurfaced in 20231, 20241, 20242, 20252, 20262 and now tops the current list. It even had its own reversal quarter, the sharpest decliner on record in 20213. A genuinely strong quarter explained by a six-year-old mechanism is a quarter you should interrogate rather than celebrate. The honest reading is that MFC is a price-and-acuity story masquerading as a growth story, and it happens to be executing the price-and-acuity story well right now. The cost side moved in step: drugs and supplies up 12.2% on case mix, consolidated salaries up 7.7% on annual merit increases plus higher market driven compensation for anesthesia nurse practitioners. Note the anesthesia detail — contracted anesthesia staffing is the quiet structural cost creep in this model, and it has now shown up repeatedly.

The Headwind That Vanished

The most revealing thing in this quarter is an absence. For six consecutive quarters, one keyword sat near the top of this company's list: Sioux Falls. It ranked first in 20252 with the highest momentum score of any term that quarter, and it recurred in 20251, 20241, 20242, 20232 and 20231. A year ago the CFO was still quantifying the damage: “If you look at the impact just on the revenue overall, it was certainly down about $3.9 million for the quarter.” — David N. T. Watson, Chief Financial Officer · 2025-08-08 And the CEO promised it was finished: “we think that the relocation impact is behind us.” — Jason P. Redman, Chief Executive Officer · 2025-08-08 He was right. In 20264, Sioux Falls does not appear at all. Neither does credit facility — a top-two theme in both 20252 and 20244 — because the corporate revolver was repaid in 2024. Neither does Arkansas surgical hospital, which ranked second as recently as 20262, nor "competitive environment." That is a real change in the story: the geographic and balance-sheet problems that framed every call from 2023 through mid-2025 have been resolved, and the narrative has shifted to mix and capital return. Investors who own this for the troubled-asset-recovery trade should notice the trade is largely done.

The Buyback Is the Actual Thesis

With the operational noise cleared, the capital-return machine is what is left. “We fully utilized our normal course issuer bid purchase limit of approximately 1.8 million common shares by mid-July” — Jason Redman · 2026-11-12 — 1.7 million shares for $21.5 million through nine months, against a market cap near $193 million. Since the change in corporate strategy in Q3 2022, MFC has returned roughly CAD 219.6 million through a combination of NCIBs, substantial issuer bids and dividends. Stack that against the balance sheet: $70.8 million of consolidated cash, $60.7 million of it at the corporate level, and zero corporate debt. That corporate cash alone is a large fraction of the equity value. The company also has no obligation to deploy it quickly — the Oklahoma Spine Hospital sale in Q1 is what inflated the cash pile, and management has shown it will sit on proceeds rather than force a deal. On a $193 million cap, an NCIB of this size is materially accretive per share, which is a more reliable driver of returns than a 1-point mix improvement in any single quarter.

There are no questions at this time. I'd now like to turn the call back over to Mr. Redman for final closing comments.

Operator · 2026-11-12

The Silence Is the Signal

That is the second consecutive quarter with an empty Q&A — the 2026-08-06 call ended the same way. Which matters, because a year ago the analyst questions were exactly the right ones. In 2025-08-08, RBC's Sahil Dhingra pressed on Sioux Falls, on the new credit facility, on competition in Arkansas, and on reimbursement risk. Watson's answer on the last one was dismissive but specific: “Medicaid really represents an immaterial portion of our business.” — David N. T. Watson, Chief Financial Officer · 2025-08-08 And Redman on site-neutrality legislation had said it was “too early to predict what that impact is because no one knows what the legislation could be.” — Jason Redman, Chief Executive Officer · 2025-03-13 None of that was asked this quarter. Not because it resolved, but because nobody called in. That is a coverage problem, not a risk all-clear. And the policy risk has not gone away — if anything, the market is now voting on the surrounding themes. Site of service has been a persistent advancer on both the 360-day and 90-day tape, and Medicaid work requirements showed up among the 90-day gainers alongside hospital operators. Meanwhile ambulatory surgery centers and acute-care hospitals are both in the 90-day advancer cohort. The sector's tape is warm and the reimbursement question is live for the industry — MFC simply stopped being asked about it, because at $193 million with one covering analyst and vanishingly little news flow, the company has drifted below the institutional radar.

Bottom Line

Medical Facilities is a small, cash-rich, debt-free surgery center operator that just posted its best operating quarter in years on mix and rate rather than volume, has finished unwinding its Sioux Falls problem, and is returning capital at a pace that makes the share count shrink faster than the business grows. The bear case is equally clean: with volumes negative and the growth engine being a perennially recycled Payer mix and acuity story, there is no organic volume catalyst, and the anesthesia wage line is rising. And with no price tape available for this name and no press coverage in the window, the market's verdict is unknown — which is, in its own way, the point. A company this quiet can stay cheap for a long time.